A Phase 2 interventional study of Nalfurafine hydrochloride(MT-9938) 2.5μg and Nalfurafine hydrochloride(MT-9938) 5μg in Uremic Pruritus, sponsored by Toray Industries, Inc. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Toray Industries, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing TRK 820 in Pruritus — 3 open to participants now, 3 under way, none of them phase 3. TRK 820 · Pruritus.
Among the 10 studies testing TRK 820 in Pruritus, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 2 in phase 2, and was the 4th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →3 of the 10 studies testing TRK 820 in Pruritus are open now, in 1 country. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 18–85
Indonesia University
Ages 18–65
Chinese PLA General Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2012.
This study's enrollment of 45 is below the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 99 across the 10 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 8 most frequent:
Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Toray Industries, Inc has 3 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
1 of the studies testing TRK 820 in Pruritus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07098351Guangdong Provincial People's HospitalEfficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing TRK 820 in Pruritus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to investigate the efficacy of MT-9938 compared with placebo after 2 weeks, to continue to evaluate efficacy for an additional 6 weeks, and to explore the effect of a reduction in itching intensity on health-related Quality of Life(QoL) domains, especially those which recent research suggests have a positive correlation with overall survival for this patient group. The study will consist of the following phases: Screening (1 to 2 weeks), Run in (1 week), double-blind Treatment (8 weeks), Washout (1 week) culminating in a Follow-up Visit (1 week after the last dose).
This study has been terminated because of insufficient patient recruitment. There were no safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nalfurafine hydrochloride(MT-9938) 2.5μg
Drug: Nalfurafine hydrochloride(MT-9938) 5μg
Drug: Nalfurafine hydrochloride(MT-9938) 10μg
Drug: Placebo
2.5 μg (2capsules) once daily for 8 weeks
5 μg (2capsules) once daily for 8 weeks
10 μg (2capsules) once daily for 8 weeks
Placebo (2capsules) once daily for 8 weeks
Change From Baseline in Worst-itching 11-point Numerical Rating Scale (NRS)
The subject indicated the number on the line from left (0:no itching) to right (10:worst itch I have ever experienced). Assessments was made twice daily using an electronic Patient Reported Outcomes (ePRO) device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, at approximately 8 am and at approximately 8 pm. Subjects selected the number that best described the worst itch during the day (assessed at approximately 8 pm) or during the night (assessed at approximately 8 am). The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline (average over the Run-in Phase \[Days -7 to -1\]) score in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
Time frame: 2 weeks, 4 weeks and 8 week
Change From Baseline in Worst-itching Visual Analog Scale (VAS)
The subject placed a single vertical mark on the line of a VAS corresponding to degree of itching intensity from left (no itching) to right (worst itch I have ever experienced). The VAS represents a 100 mm line. It consists of 101 selectable regions and the subject's score on the VAS will correspond to the region (0 to 100) selected on the line. Assessments was made twice daily using an ePRO device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, in the morning at approximately 8 am and in the night at approximately 8 pm. Subjects put a single vertical mark on the line to show the intensity of your worst itching during the day or during the night. The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
Time frame: 2 weeks, 4 weeks and 8 weeks
Change From Baseline in Itch Severity Score
The subject performed an assessment on day and nighttime symptoms of itch and effect of itch on sleep using a 5-point ordinal scale of itchiness (0 = none, 1 = mild, 2 = Moderate, 3=Severe, 4 = very severe). Assessments was made during each dialysis treatment (3x/week) and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9). Change from Baseline (average over the Run-in Phase \[Days -7 to -1\]) in Weekly Averages of Itch Severity Score were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
Time frame: 2 weeks, 4 weeks and 8 weeks
Change From Baseline in Sleep Quality Assessment
The PSQI has a minimum possible score of 0 (better sleep quality) and a maximum possible score of 10 (worse sleep quality). Subjects was asked to rate their sleep experience during the previous week. Pittsburgh Sleep Quality Index (PSQI) modified assessment was made during the dialysis treatment 1x/week every week and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9).Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
Time frame: 2 weeks, 4 weeks and 8 weeks
Change From Baseline in QoL Assessment (Skindex-10)
The Skindex-10 has a minimum possible score of 0 (itching not bothersome) and a maximum possible score of 60 (itching very bothersome). The Skindex-10 is a self-administered questionnaire used to evaluate the health-related QoL in UP. It is comprised of 10 questions, adopted for pruritus from the Skindex-16, a widely used instrument for a variety of skin disease. Subjects was asked to identify on paper at Baseline and Weeks 2, 4, and 8 (EOT) what has bothered them most during the past week by marking along a scale 0 to 6 boxes from "never bothered" to "always bothered. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.
Time frame: 2 weeks, 4 weeks and 8 weeks
The Mean Value in Treatment Satisfaction (Patient's Global Impression of Change )
The PGIC has a minimum possible score of 1 (very much improved) and a maximum possible score of 7 (very much worse). Subjects was asked to use a categorical scale with 7 categories to describe their global impression of change (PGIC) with study drug treatment. Subjects recorded their impression of change on paper at Weeks 2, 4, and 8 (EOT). Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the mean value of patients at each point is shown instead.
Time frame: 2 weeks, 4 weeks and 8 weeks
Change From Baseline in QoL Assessment (5-D-Itch Scale)
The 5-D-Itch scale has a minimum possible score of 5 (better) and a maximum possible score of 25 (worse). Subjects was asked to assess QoL by means of the 5D-Itch-Scale at Baseline, Weeks 2, 4, and 8 (EOT). The 5D-Itch Scale is a 5-item (duration, degree, direction, disability, and distribution) multidimensional measure of pruritus itch. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.
Time frame: 2 weeks, 4 weeks and 8 weeks
The Number of Patients in Excoriation
Investigator and/or the designated medically qualified staff assessed the subject's excoriation at Baseline, and weekly thereafter, by completing the subject's answers to the following questions: Excoriation present? Yes/No If yes, please rate the severity: Mild/Moderate/Severe Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the number of patients at each point is shown instead.
Time frame: 2 weeks, 4 weeks and 8 weeks
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
The number of subjects with at least 1 treatment-emergent adverse event (TEAE). Please see the adverse event table for specific.
Time frame: 8 weeks
| Milestone | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| Started | 10 | 13 | 11 | 11 |
| Completed | 8 | 13 | 9 | 10 |
| Not completed | 2 | 0 | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
| Withdrew: Unable to visit clinic to obtain study drug due to hospitalization | 1 | 0 | 0 | 0 |
| Withdrew: Subject was noncompliant with study drug after experiencing aes; was not discontinued due to the aes | 0 | 0 | 1 | 0 |
| Withdrew: Randomization error | 0 | 0 | 0 | 1 |
The subject indicated the number on the line from left (0:no itching) to right (10:worst itch I have ever experienced). Assessments was made twice daily using an electronic Patient Reported Outcomes (ePRO) device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, at approximately 8 am and at approximately 8 pm. Subjects selected the number that best described the worst itch during the day (assessed at approximately 8 pm) or during the night (assessed at approximately 8 am). The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline (average over the Run-in Phase \[Days -7 to -1\]) score in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
| score on a scale | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| At 2 weeks | -1.11 ± 1.224 | -1.19 ± 1.177 | -1.12 ± 0.828 | -2.27 ± 2.774 |
| At 4 weeks | -1.41 ± 2.032 | -2.12 ± 2.527 | -1.85 ± 1.392 | -2.25 ± 3.114 |
| At 8 weeks (EOT) | -2.33 ± 2.269 | -3.13 ± 2.833 | -3.42 ± 2.262 | -3.39 ± 3.614 |
The subject placed a single vertical mark on the line of a VAS corresponding to degree of itching intensity from left (no itching) to right (worst itch I have ever experienced). The VAS represents a 100 mm line. It consists of 101 selectable regions and the subject's score on the VAS will correspond to the region (0 to 100) selected on the line. Assessments was made twice daily using an ePRO device from the Screening Visit to the Follow-up Visit (Week 9). The 2 daily assessments was separated by 12 h, in the morning at approximately 8 am and in the night at approximately 8 pm. Subjects put a single vertical mark on the line to show the intensity of your worst itching during the day or during the night. The day or night score, whichever was greater, was used to calculate the weekly average score and changes from baseline in weekly average at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
| mm | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| At 2 weeks | -8.77 ± 15.158 | -12.27 ± 12.154 | -6.56 ± 18.778 | -21.09 ± 26.719 |
| At 4 weeks | -14.17 ± 22.631 | -19.46 ± 25.097 | -21.24 ± 20.300 | -23.63 ± 31.239 |
| At 8 weeks (EOT) | -23.06 ± 23.686 | -29.16 ± 27.628 | -24.49 ± 42.732 | -30.09 ± 31.582 |
The subject performed an assessment on day and nighttime symptoms of itch and effect of itch on sleep using a 5-point ordinal scale of itchiness (0 = none, 1 = mild, 2 = Moderate, 3=Severe, 4 = very severe). Assessments was made during each dialysis treatment (3x/week) and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9). Change from Baseline (average over the Run-in Phase \[Days -7 to -1\]) in Weekly Averages of Itch Severity Score were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
| score on a scale | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| At 2 weeks | -0.77 ± 0.721 | -0.77 ± 0.542 | -0.43 ± 0.872 | -0.92 ± 1.106 |
| At 4 weeks | -0.81 ± 0.835 | -1.08 ± 0.741 | -1.30 ± 0.885 | -0.90 ± 1.275 |
| At 8 weeks (EOT) | -1.13 ± 1.003 | -1.49 ± 0.919 | -1.28 ± 1.094 | -1.28 ± 1.197 |
The PSQI has a minimum possible score of 0 (better sleep quality) and a maximum possible score of 10 (worse sleep quality). Subjects was asked to rate their sleep experience during the previous week. Pittsburgh Sleep Quality Index (PSQI) modified assessment was made during the dialysis treatment 1x/week every week and recorded on paper from the Screening Visit to the Follow-up Visit (Week 9).Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed and score at 2, 4 and 8 weeks as specified in the protocol are reported. Amount of change score of plus indicates worsening, and minus indicates improvement.
| score on a scale | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| At 2 weeks | -0.4 ± 1.06 | -0.2 ± 2.17 | -0.2 ± 1.64 | -1.0 ± 1.15 |
| At 4 weeks | -0.4 ± 1.92 | -0.3 ± 1.65 | -1.1 ± 1.36 | -0.1 ± 1.36 |
| At 8 weeks (EOT) | -1.1 ± 1.35 | -0.6 ± 1.62 | -1.2 ± 1.55 | -0.4 ± 1.59 |
The Skindex-10 has a minimum possible score of 0 (itching not bothersome) and a maximum possible score of 60 (itching very bothersome). The Skindex-10 is a self-administered questionnaire used to evaluate the health-related QoL in UP. It is comprised of 10 questions, adopted for pruritus from the Skindex-16, a widely used instrument for a variety of skin disease. Subjects was asked to identify on paper at Baseline and Weeks 2, 4, and 8 (EOT) what has bothered them most during the past week by marking along a scale 0 to 6 boxes from "never bothered" to "always bothered. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.
| score on a scale | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| At 2 weeks | -5.5 ± 8.55 | -11.6 ± 11.16 | -5.4 ± 9.27 | -13.6 ± 15.21 |
| At 4 weeks | -0.5 ± 14.99 | -16.5 ± 15.00 | -16.4 ± 14.55 | -13.7 ± 17.68 |
| At 8 weeks (EOT) | -11.9 ± 5.61 | -23.5 ± 15.52 | -19.2 ± 14.59 | -16.3 ± 14.63 |
The PGIC has a minimum possible score of 1 (very much improved) and a maximum possible score of 7 (very much worse). Subjects was asked to use a categorical scale with 7 categories to describe their global impression of change (PGIC) with study drug treatment. Subjects recorded their impression of change on paper at Weeks 2, 4, and 8 (EOT). Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the mean value of patients at each point is shown instead.
| units on a scale | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| 2 weeks | 3.1 ± 0.64 | 3.1 ± 1.51 | 3.0 ± 0.87 | 2.6 ± 1.07 |
| 4 weeks | 3.3 ± 0.71 | 2.8 ± 1.36 | 2.5 ± 0.93 | 2.8 ± 1.09 |
| 8 weeks | 2.6 ± 0.98 | 1.9 ± 0.90 | 2.1 ± 1.17 | 2.2 ± 1.30 |
The 5-D-Itch scale has a minimum possible score of 5 (better) and a maximum possible score of 25 (worse). Subjects was asked to assess QoL by means of the 5D-Itch-Scale at Baseline, Weeks 2, 4, and 8 (EOT). The 5D-Itch Scale is a 5-item (duration, degree, direction, disability, and distribution) multidimensional measure of pruritus itch. Change from Baseline (the Run-in Phase \[Days -7 to -1\]) were assessed. Amount of change score of plus indicates worsening, and minus indicates improvement.
| score on a scale | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| At 2 weeks | -2.8 ± 2.12 | -3.3 ± 2.46 | -3.0 ± 2.62 | -6.1 ± 5.84 |
| At 4 weeks | -1.6 ± 4.17 | -5.1 ± 3.80 | -5.6 ± 3.16 | -5.7 ± 5.02 |
| At 8 weeks | -3.7 ± 3.90 | -8.6 ± 4.25 | -6.2 ± 5.01 | -7.6 ± 4.53 |
Investigator and/or the designated medically qualified staff assessed the subject's excoriation at Baseline, and weekly thereafter, by completing the subject's answers to the following questions: Excoriation present? Yes/No If yes, please rate the severity: Mild/Moderate/Severe Although the change from baseline (run-in phase \[Days -7 to -1\]) was specified as an outcome in this study, it was not calculated because the target enrollment was not met and no meaningful statistical analysis could be expected. Therefore, the number of patients at each point is shown instead.
| Participants | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| Baseline — Excoriation not present | 7 | 6 | 7 | 7 |
| Baseline — Mild | 2 | 4 | 3 | 2 |
| Baseline — Moderate | 1 | 2 | 1 | 2 |
| Baseline — Severe | 0 | 0 | 0 | 0 |
| Baseline — Missing | 0 | 0 | 0 | 0 |
| 2 weeks — Excoriation not present | 6 | 7 | 7 | 7 |
| 2 weeks — Mild | 2 | 5 | 2 | 3 |
| 2 weeks — Moderate | 0 | 0 | 0 | 0 |
| 2 weeks — Severe | 0 | 0 | 0 | 0 |
| 2 weeks — Missing | 0 | 0 | 0 | 0 |
| 4 weeks — Excoriation not present | 6 | 11 | 7 | 7 |
| 4 weeks — Mild | 2 | 2 | 1 | 2 |
| 4 weeks — Moderate | 0 | 0 | 0 | 1 |
| 4 weeks — Severe | 0 | 0 | 0 | 0 |
| 4 weeks — Missing | 0 | 0 | 0 | 0 |
| 8 weeks — Excoriation not present | 6 | 9 | 9 | 7 |
| 8 weeks — Mild | 1 | 2 | 0 | 1 |
| 8 weeks — Moderate | 0 | 1 | 0 | 0 |
| 8 weeks — Severe | 0 | 0 | 0 | 1 |
| 8 weeks — Missing | 0 | 0 | 0 | 0 |
The number of subjects with at least 1 treatment-emergent adverse event (TEAE). Please see the adverse event table for specific.
| Participants | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability | 6 | 5 | 9 | 6 |
Collected over 8 weeks for treatment phase + 1 week follow-up visit after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-9938 2.5μg | 0/10 (0%) | 4/10 (40%) | 2/10 (20%) |
| MT-9938 5μg | 0/13 (0%) | 0/13 (0%) | 2/13 (15.4%) |
| MT-9938 10μg | 0/11 (0%) | 3/11 (27.3%) | 5/11 (45.5%) |
| Placebo | 0/11 (0%) | 2/11 (18.2%) | 3/11 (27.3%) |
| Event | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| Cardiac Failure CongestiveCardiac disorders | 0/10 | 0/13 | 2/11 | 0/11 |
| DiverticulitisInfections and infestations | 1/10 | 0/13 | 0/11 | 0/11 |
| Fluid OverloadMetabolism and nutrition disorders | 1/10 | 0/13 | 0/11 | 0/11 |
| HypercalcaemiaMetabolism and nutrition disorders | 1/10 | 0/13 | 0/11 | 0/11 |
| Pancreatitis RelapsingGastrointestinal disorders | 1/10 | 0/13 | 0/11 | 0/11 |
| CellulitisInfections and infestations | 0/10 | 0/13 | 1/11 | 0/11 |
| PneumoniaInfections and infestations | 0/10 | 0/13 | 0/11 | 1/11 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 0/13 | 1/11 | 0/11 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/10 | 0/13 | 1/11 | 0/11 |
| AstheniaGeneral disorders | 0/10 | 0/13 | 0/11 | 1/11 |
| Event | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 1/10 | 1/13 | 5/11 | 1/11 |
| NauseaGastrointestinal disorders | 1/10 | 0/13 | 3/11 | 1/11 |
| HyperprolactinaemiaEndocrine disorders | 1/10 | 1/13 | 0/11 | 1/11 |
ITT
| Age, Continuous(years) | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 58.5 ± 10.62 | 54.6 ± 12.78 | 55.3 ± 13.64 | 55.2 ± 12.94 | 55.8 ± 12.25 |
| Sex: Female, Male(Participants) | MT-9938 2.5μg | MT-9938 5μg | MT-9938 10μg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 2 | 2 | 4 | 13 |
| Male | 5 | 11 | 9 | 7 | 32 |
The record gives a start of Sep 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2022, 7 years 11 months after primary completion. A results delay was requested in Oct 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TRK 820
Toray Industries, Inc